Literature DB >> 25135483

p38 MAPK in pancreatic cancer: finding a protective needle in the haystack.

Murray Korc1.   

Abstract

Activated p38 MAPK alpha (pp38α) is a good prognostic marker in pancreatic ductal adenocarcinoma that could be used to personalize therapy. pp38α suppresses JNK-mediated proliferation, both in vitro and in vivo. These findings support the testing of combination therapies that include JNK targeting and/or suppressing negative regulators of pp38α. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25135483      PMCID： PMC4254114          DOI： 10.1158/1078-0432.CCR-14-1543

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Kinase signaling pathways as targets for intervention in pancreatic cancer.

Authors:  Meir Preis; Murray Korc
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

Review 2.  Mechanisms and functions of p38 MAPK signalling.

Authors:  Ana Cuadrado; Angel R Nebreda
Journal:  Biochem J       Date:  2010-08-01       Impact factor: 3.857

Review 3.  Signal integration by JNK and p38 MAPK pathways in cancer development.

Authors:  Erwin F Wagner; Angel R Nebreda
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

4.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

Review 5.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

6.  p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway.

Authors:  Lijian Hui; Latifa Bakiri; Andreas Mairhorfer; Norbert Schweifer; Christian Haslinger; Lukas Kenner; Vukoslav Komnenovic; Harald Scheuch; Hartmut Beug; Erwin F Wagner
Journal:  Nat Genet       Date:  2007-04-29       Impact factor: 38.330

7.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

8.  Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.

Authors:  Quan Liao; Junchao Guo; Jörg Kleeff; Arthur Zimmermann; Markus W Büchler; Murray Korc; Helmut Friess
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

9.  DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.

Authors:  Fang Liu; A Jesse Gore; Julie L Wilson; Murray Korc
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

10.  Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.

Authors:  Masashi Okada; Keita Shibuya; Atsushi Sato; Shizuka Seino; Shuhei Suzuki; Manabu Seino; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2014-07-15
View more
  3 in total

1.  The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma.

Authors:  Jie Zhang; Keqing Shi; Weiguo Huang; Wanqing Weng; Zhongjing Zhang; Yangyang Guo; Tuo Deng; Yukai Xiang; Xiaofeng Ni; Bicheng Chen; Mengtao Zhou
Journal:  Cancer Cell Int       Date:  2019-04-23       Impact factor: 5.722

2.  Requirement for epithelial p38α in KRAS-driven lung tumor progression.

Authors:  Jessica Vitos-Faleato; Sebastián M Real; Nuria Gutierrez-Prat; Alberto Villanueva; Elisabet Llonch; Matthias Drosten; Mariano Barbacid; Angel R Nebreda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-22       Impact factor: 11.205

3.  TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Authors:  Silvia Ottaviani; Justin Stebbing; Adam E Frampton; Sladjana Zagorac; Jonathan Krell; Alexander de Giorgio; Sara M Trabulo; Van T M Nguyen; Luca Magnani; Hugang Feng; Elisa Giovannetti; Niccola Funel; Thomas M Gress; Long R Jiao; Ylenia Lombardo; Nicholas R Lemoine; Christopher Heeschen; Leandro Castellano
Journal:  Nat Commun       Date:  2018-05-10       Impact factor: 14.919
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.